A Phase 3 Study to Evaluate Efficacy and Safety of HDM1002 Tablets in Adults With Type 2 Diabetes Mellitus

This Phase 3 study is testing a new oral tablet called HDM1002 as an add-on treatment for adults with Type 2 diabetes whose blood sugar is not well controlled on metformin alone. The goal is to see if HDM1002 can help lower blood sugar levels (HbA1c) safely and effectively. **You may be eligible if...** - You are between 18 and 75 years old with Type 2 diabetes diagnosed at least 3 months ago - You have been taking a stable dose of metformin (at least 1500 mg per day or the maximum tolerated dose) for at least 8 weeks - Your HbA1c (a 3-month blood sugar average) is between 7.5% and 11% - Your BMI is between 19 and 40 **You may NOT be eligible if...** - You have Type 1 diabetes or any form other than Type 2 - You have had a recent serious heart event, stroke, or uncontrolled heart failure within the past 3 months - You have a history of pancreatitis, thyroid cancer, or severe digestive problems - You are pregnant, breastfeeding, or have taken a GLP-1 drug (such as semaglutide) in the past 3 months Talk to your doctor to see if this trial is right for you.